Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Osivelotor in Hepatic Impairment
NCT06340347Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of osivelotor in sickle cell disease (SCD) (2 arms), sponsored by Pfizer. Primary endpoints: Area under the concentration-time curve from time zero to the last quantifiable concentration, Area under the concentration-time curve from time zero to extrapolated infinite time and 1 more. Started Apr 2024; status: completed.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06340347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340347.